Healthcare / Drug Manufacturers - Specialty & GenericBSE
$75.40
-1.31 (-1.71%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $79.1M · quality 47.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
50/100
C
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$7.6B
P/E
18.4x
↓EV/EBITDA
11.3x
↓ROE
11.7%
↑Gross Margin
22.3%
↓Debt/Equity
0.00
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2023–2026 · 3 años de histórico normalizado
Revenue CAGR
+13.5%
FCF CAGR
—
FCF margin
-1.4%
FCF / Net income
-0.27x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $7.72B · net income $410.5M · FCF $-108.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $7.72B | $7.72B | $6.62B | $6.47B | $5.27B |
| Net Income | $410.5M | $410.5M | $473.5M | $600.6M | $361.8M |
| EBITDA | $660.8M | $660.8M | $703.6M | $872.5M | $573.9M |
| EPS | 4.10 | 4.10 | 4.72 | 5.99 | 3.61 |
| Gross Margin | 22.3% | 22.3% | 24.5% | 24.8% | 23.9% |
| Operating Margin | 6.5% | 6.5% | 7.9% | 10.5% | 8.4% |
| Net Margin | 5.3% | 5.3% | 7.2% | 9.3% | 6.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.00 | 0.00 | 0.03 | 0.01 | 0.00 |
| Current Ratio | 2.22 | 2.22 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-108.8M | $-108.8M | $169.8M | $79.1M | $523.5M |
| Returns | |||||
| ROE | 11.7% | 11.7% | 14.5% | 20.6% | 15.0% |
| Valuation | |||||
| P/E | 18.39 | 18.39 | 18.69 | 20.87 | 11.90 |
| EV/EBITDA | 11.30 | 11.30 | 12.45 | 14.31 | 7.48 |
| P/B | 2.14 | 2.14 | 2.71 | 4.30 | 1.78 |
| Growth & Yield | |||||
| Revenue Growth | 16.7% | 16.7% | 2.2% | 22.7% | — |
| EPS Growth | -13.1% | -13.1% | -21.2% | 65.9% | — |
| Dividend Yield | 2.0% | 2.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
17.7%
EPS terminal req.
$6.69
Spread vs growth
-30.9%
5Y implied EPS CAGR
14.6%
EPS terminal req.
$8.10
Spread vs growth
-27.7%
10Y implied EPS CAGR
12.3%
EPS terminal req.
$13.04
Spread vs growth
-25.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.4%
Start / end P/E
21.7x → 18.4x
EPS bridge
4.72 → 4.10
Residual
+2.0%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.